Abstract
Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India.
Keywords: Clinical trials, review, tuberculosis, tuberculosis vaccines.
Infectious Disorders - Drug Targets
Title:Tuberculosis Vaccines: Hopes and Hurdles
Volume: 13 Issue: 5
Author(s): Mohamed J. Ahsan, Shiv K. Garg, Bharat Vashistha and Piush Sharma
Affiliation:
Keywords: Clinical trials, review, tuberculosis, tuberculosis vaccines.
Abstract: Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India.
Export Options
About this article
Cite this article as:
Ahsan J. Mohamed, Garg K. Shiv, Vashistha Bharat and Sharma Piush, Tuberculosis Vaccines: Hopes and Hurdles, Infectious Disorders - Drug Targets 2013; 13 (5) . https://dx.doi.org/10.2174/1871526513666131201125513
DOI https://dx.doi.org/10.2174/1871526513666131201125513 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Properties of Yeast-based Mannoprotein for Prospective Biomedical Applications
Combinatorial Chemistry & High Throughput Screening Nontuberculous Mycobacterium Infections in Rheumatoid Arthritis Patients: The Serodiagnosis of Pulmonary Disease due to Mycobacterium avium Complex with an Enzyme Immunoassay Kit Detecting Glycopeptidolipid Core Antigen (Capilia MAC Antibody ELISA)<sup>®</sup>)
Current Rheumatology Reviews 4-Hydroxy-3-methoxyphenyl Substituted 3-methyl-tetrahydroquinoline Derivatives Obtained Through Imino Diels-Alder Reactions as Potential Antitumoral Agents
Letters in Drug Design & Discovery Structure and Function of MPN (Mpr1/Pad1 N-terminal) Domain- Containing Proteins
Current Protein & Peptide Science Advancement in Vaccinology: New Era in Formulation Strategies
Current Drug Therapy Structure-Activity Design, Synthesis and Biological Activity of Newer Imidazole- Triazine Clubbed Derivatives as Antimicrobial and Antitubercular Agents
Letters in Organic Chemistry The Medicinal Chemistry of 3-nitro-1,2,4-triazoles: Focus on Infectious Diseases
Current Topics in Medicinal Chemistry The Long Pentraxin PTX3, a Soluble Pattern Recognition Receptor Involved in Innate Immunity,Inflammation and Female Fertility
Current Immunology Reviews (Discontinued) Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Chemical Composition and Antibacterial Potential of Essential Oils from Artemisia Capillaris, Artemisia Nilagirica, Citrus Limon, Cymbopogon Flexuosus, Hedychium Spicatum and Ocimum Tenuiflorum
The Natural Products Journal Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy
Current Medicinal Chemistry Drugs that Inhibit Mycolic Acid Biosynthesis in Mycobacterium tuberculosis
Current Pharmaceutical Biotechnology Monoclonal Antibodies in Allergy; Updated Applications and Promising Trials
Recent Patents on Inflammation & Allergy Drug Discovery <i>Larrea tridentata</i> and its Biological Activities
Current Topics in Medicinal Chemistry A Guide to Treatment of Sarcoidosis
Current Drug Therapy C-type Lectin Receptor: Old Friend and New Player
Medicinal Chemistry Inflammation and Innate Immune Response Against Viral Infections in Marine Fish
Current Pharmaceutical Design Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy
Current Cancer Therapy Reviews Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review
Reviews on Recent Clinical Trials New Chemotherapy and Immunotherapy for Tuberculosis
Current Respiratory Medicine Reviews